The broader move into defensive sectors hit a snag with Moderna, which saw shares tumble following the unauthorized release of sensitive data from an mRNA-based cancer vaccine trial. While the company and partner Merck previously touted successful results in August—specifically citing the vaccine's efficacy in preventing melanoma recurrence—the breach of trial confidentiality on social media rattled stakeholders.

This volatility underscores the sensitivity surrounding clinical data in the biotech space, even as the wider sector benefits from the defensive rotation. Investors remain cautious, balancing the long-term potential of mRNA therapeutics against the immediate impact of procedural setbacks.